Efdamrofusp alfa

依莫芙普α

Report date: 2026/05/02 20:00:18
First In Class

Base Information

Drug NameEfdamrofusp alfa
Drug Alias Name重组人血管内皮生长因子受体-抗体-人补体受体1融合蛋白注射液IBI-302
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionVascular endothelial growth factor inhibitorsComplement C3 inhibitorsComplement C4-B inhibitors
TargetsVascular endothelial growth factorComplement C3Complement C4-B
Therapy Area/IndicationsPlaque psoriasisDiabetic macular oedemaWet age-related macular degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAP Biosciences Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics Technology LtdInnovent Biologics(Suzhou) Co LtdBiologics Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisDiabetic macular oedemaMacular Degeneration
Inactive IndicationsWet age-related macular degeneration

Other Information

ATC CodeN/A
Related LinksN/A